Vyome Holdings, Inc
HIND · XNASCIK 1427570fmd_0X8SJV44TMTE4R99BK309GCJGFManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2014 to Sep 30, 2026, 48 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 10 | 9 | 3 | 11 | 14 | 11 | 9 | 0 | 0 |
| Cost of revenue | 3 | 5 | 5 | 3 | 5 | 5 | 4 | 3 | 0 | 0 |
| Gross profit | 1 | 5 | 4 | 0 | 6 | 8 | 7 | 6 | 0 | 0 |
| Research and development | 10 | 11 | 11 | 7 | 3 | 2 | 3 | 2 | 0 | 1 |
| Selling, general and administrative | 10 | 29 | 30 | 17 | 5 | 9 | 14 | 18 | 1 | 2 |
| Total operating expenses | 20 | 39 | 41 | 24 | 19 | 66 | 53 | 21 | 1 | 11 |
| Operating income | (20) | (34) | (37) | (23) | (12) | (58) | (46) | (15) | (1) | (10) |
| Interest expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Other non-operating income (expense) | (0) | (0) | (0) | (0) | (0) | – | 0 | 0 | (0) | (0) |
| Income before taxes | – | – | – | – | (22) | (63) | (47) | (11) | (7) | – |
| Income tax expense | 0 | 0 | 0 | 0 | (0) | (0) | (0) | 0 | 0 | – |
| Net income from continuing operations | – | – | – | – | (22) | (63) | (46) | (11) | (7) | – |
| Net income | (20) | (35) | (37) | (24) | (22) | (63) | (46) | (11) | (1) | (10) |
| Net income to common shareholders | – | – | – | – | (22) | (63) | (46) | (11) | – | – |